NAMA
CRSP icon

Nikko Asset Management Americas’s CRISPR Therapeutics CRSP Stock Holding History

Nikko Asset Management Americas’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.2M Sell
1,853,875
-104,236
-5% -$5.5M 1.25% 26
2025
Q4 		$103M Sell
1,958,111
-205,564
-10% -$12.3M 1.19% 24
2025
Q3 		$140M Sell
2,163,675
-250,596
-10% -$14.4M 1.36% 19
2025
Q2 		$117M Sell
2,414,271
-125,618
-5% -$4.86M 1.17% 23
2025
Q1 		$86.3M Sell
2,539,889
-205,787
-7% -$8.72M 1.11% 24
2024
Q4 		$108M Sell
2,745,676
-221,543
-7% -$10.5M 1.17% 25
2024
Q3 		$139M Sell
2,967,219
-184,295
-6% -$9.35M 1.58% 19
2024
Q2 		$170M Sell
3,151,514
-117,271
-4% -$6.78M 1.96% 16
2024
Q1 		$223M Sell
3,268,785
-100,977
-3% -$7.23M 2.21% 13
2023
Q4 		$211M Sell
3,369,762
-95,708
-3% -$5.29M 2.03% 13
2023
Q3 		$157M Sell
3,465,470
-67,887
-2% -$3.51M 1.88% 14
2023
Q2 		$198M Sell
3,533,357
-438,782
-11% -$24.9M 2.09% 15
2023
Q1 		$179M Sell
3,972,139
-34,337
-0.9% -$1.67M 2.06% 16
2022
Q4 		$163M Sell
4,006,476
-256,260
-6% -$13.6M 2.35% 14
2022
Q3 		$277M Sell
4,262,736
-321,362
-7% -$23.3M 3.54% 9
2022
Q2 		$276M Sell
4,584,098
-35,649
-0.8% -$2.1M 3.41% 9
2022
Q1 		$291M Buy
4,619,747
+300,276
+7% +$18.9M 2.14% 15
2021
Q4 		$331M Buy
4,319,471
+1,029,955
+31% +$90M 1.74% 17
2021
Q3 		$368M Sell
3,289,516
-93,940
-3% -$11.8M 1.58% 21
2021
Q2 		$548M Sell
3,383,456
-276,409
-8% -$33.6M 2.15% 13
2021
Q1 		$446M Sell
3,659,865
-176,958
-5% -$26.7M 2.18% 11
2020
Q4 		$587M Buy
3,836,823
+139,156
+4% +$16.4M 3.34% 4
2020
Q3 		$309M Sell
3,697,667
-14,303
-0.4% -$1.27M 2.74% 7
2020
Q2 		$269M Sell
3,711,970
-54,571
-1% -$3.19M 3.53% 5
2020
Q1 		$160M Buy
3,766,541
+716,988
+24% +$37M 2.97% 6
2019
Q4 		$186M Buy
3,049,553
+272,139
+10% +$14.9M 2.92% 6
2019
Q3 		$114M Buy
2,777,414
+906,006
+48% +$43.3M 2.02% 13
2019
Q2 		$88.1M Buy
1,871,408
+1,430,364
+324% +$57.2M 1.73% 16
2019
Q1 		$15.8M Buy
441,044
+440,120
+47,632% +$15.2M 0.42% 50
2018
Q4 		$26K Sell
924
-200
-18% -$6.95K ﹤0.01% 137
2018
Q3 		$50K Buy
+1,124
New +$58.9K ﹤0.01% 132

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nikko Asset Management Americas's CRSP Position: Q1 2026 in Review

Nikko Asset Management Americas reduced its CRISPR Therapeutics (CRSP) stake by 5.3% in Q1 2026, selling an estimated $5.5M and leaving 1,853,875 shares worth $88.2M. The position accounts for 1.25% of the portfolio, ranked #26.

Nikko Asset Management Americas first reported a position in CRSP in Q3 2018 and has held it in 31 quarters since. The position peaked at $587M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Nikko Asset Management Americas held 1,853,875 shares of CRISPR Therapeutics worth $88.2M as of Q1 2026.
  • Nikko Asset Management Americas sold 104,236 CRISPR Therapeutics shares in Q1 2026, an estimated $5.5M.
  • CRISPR Therapeutics made up 1.25% of Nikko Asset Management Americas's portfolio in Q1 2026, its #26 holding.
  • Nikko Asset Management Americas first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Nikko Asset Management Americas's CRISPR Therapeutics position peaked at $587M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.